Table 1 Demographics of the patients received systemic, inhaler and systemic colistin therapy

Age ± SD

62.80 ± 18.80

66.67 ± 15.49

0.290

Gender (M/F)

50/30

33/10

0.109

Cause of admission

0.386

 Respiratory failure

26 (32.5)

6 (14)

0.025

 Septic shock

3 (3.8)

4 (9.3)

0.205

 Trauma

7 (8.8)

4 (9.3)

0.010

 Post-op resuscitation

10 (12.5)

9 (20.9)

0.217

 Acute neurological disorder

29 (36.3)

18 (41.9)

0.541

 Cardiac arrest

5 (6.3)

2 (4.7)

0.715

Duration of ICU stay ± SD

57.68 ± 56.99

47.91 ± 47.02

0.514

Duration of colistin therapy ± SD

11.21 ± 6.714

11.23 ± 6.023

0.708

Infection

 HKP

25 (31.3)

15 (34.9)

0.681

 VIP

55 (68.7)

28 (65.1)

0.681

 Creatinine at baseline ± SD

0.82 ± 0.56

1.20 ± 0.89

0.009

 Creatinine at end-of-treatment ± SD

1.65 ± 1.08

1.86 ± 1.22

0.469

 Nephrotoxic drug use

43 (53.8)

23 (53.5)

0.978

Underlying disorders

 Cerebrovascular event

17 (21.3)

11 (25.6)

0.584

 COPD

6 (7.5)

3 (7)

0.915

 CAD

28 (35)

22 (51.2)

0.081

 Diabetes mellitus

19 (23.8)

10 (23.3)

0.950

 CRF

5 (6.3)

3 (7)

0.876

Concomitant antibiotics

 Carbapenem

62 (77.5)

36 (83.7)

0.413

 Cefoperazon

sulbactam

9 (11.3)

6 (14)

0.662

 Tigecycline

5 (6.3)

2 (4.7)

0.715

 Sulbactam

2 (2.5)

2 (4.7)

0.521

 Ceftazidime

1 (1.3)

0 (0)

0.461